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Fibroblast differentiation is key cellular process that underlies the process of fibrosis, a deadly26
complication of fibrotic diseases like Scleroderma (SSc). This transition coincides with the27
overproduction of Collagen type I (COL1) and other extracellular matrix proteins. High level28
expression of the collagen type 1α2 subunit (COL1A2), requires the engagement of a far upstream29
enhancer, whose activation is strongly dependent on the AP1 factor JunB. We now report that STAT330
also binds the COL1A2 enhancer and is essential for RNA polymerase recruitment, without affecting31
JunB binding. STAT3 is required for the increased COL1A2 expression observed in myofibroblasts.32
We also report that TGFβ partially activates STAT3 and show that inhibiting STAT3 potently blocks 33 
TGFβ signalling, matrix remodelling and TGFβ-induced myofibroblast differentiation. Activation of34
STAT3 with IL6 trans-signalling alone however only increased COL1A2 protein expression, leaving35
COL1A2 mRNA levels unchanged. Our results suggest that activated STAT3 is not the limiting factor36
for collagen enhancer activation in human lung fibroblasts. Yet, a certain threshold level of STAT337
activity is essential to support activation of the COL1A2 enhancer and TGFβ signalling in fibroblasts.  38 
We propose that STAT3 operates at the post-transcriptional as well as the transcriptional level.39
40
INTRODUCTION41
Fibrosis is a major complication in many inflammatory diseases. Scleroderma (SSc) is a complex42
autoimmune disease, characterized by widespread organ fibrosis and thus serves as a model for43
pathological fibrosis (1). At the heart of the fibrotic process lies the differentiation of normal quiescent44
fibroblasts to myofibroblasts. Myofibroblasts are contractile, biosynthetic cells that actively produce45
large amounts of extracellular matrix (ECM) and remodel it by contraction. In normal wound healing46
this is an essential process, allowing wound closure and reformation of lost connective tissue to47
support re-epithelisation (1,2). In pathologic, fibrotic conditions, persistent myofibroblast activation48
sets off an unremitting, vicious cycle of ECM production and contraction that eventually remodels49
connective tissue into dense scar tissue (1,2). Transforming growth factor  (TGF) is the master50
regulator of wound healing and the gene expression programme drives myofibroblast differentiation51
and function (e.g. CTGF, COL1, α-SMA, EDA-fibronectin). (2). It is strongly implicated in the 52 
pathogenesis fibrotic diseases, including SSc (2).53
54
To support this differentiation and remodelling process, fibroblasts must increase production of55
Collagen type I (COL1), a major component of the extracellular matrix, which is composed of two56
chains, α1 (COL1A1) and α2 (COL1A2) (1-3). Functional COL1 consists of two α1 and one α2 chains 57 
tightly coiled around each other in a triple helix. The COL1 triple helices polymerise and become58
covalently cross-linked forming long fibrils. These fibrils provide a structural support for the59
attachment of cells and other extracellular matrix components.60
61
High expression of COL1A2 requires engagement of the COL1A2 far upstream enhancer (3),62
whose activation is a hallmark of myofibroblasts (3). Typically, it is active in scleroderma fibroblasts,63
which have a high proportion of myofibroblasts but it is weakly active or inactive in healthy control64
fibroblasts (3,4). There are three DNAse hypersensitive regions (HS3-5) in the COL1A2 enhancer65
(figure 1). These regions are attachment sites for transcription factors and specific deletion of HS466
appears to abolish function (3-5). Previously, we have shown that the balance between AP-1 members67
JunB and c-Jun is critical for enhancer activation (4). TGFβ activates the enhancer by stabilizing JunB 68 
and thus shifting the balance away from c-Jun. JunB then replaces c-Jun in the AP-1 site and fully69
activates the enhancer (4).70
71
The Signal Transducer and Activator of Transcription (STAT) family of transcription factors is72
important for cell growth and differentiation (6). STATs are activated in response to growth factor and73
cytokine through phosphorylation by the JAK kinases (JAK1-3 and TYK2). In addition, JAK-74
independent activation of STATs by Src and MAPK family members has been described (6). STAT375
signalling activates a negative feedback loop by upregulating SOCS3 (7). STAT3 signalling has been76
implicated in fibrosis (particularly in the lung) (8-10), ECM regulation (10,11) and TGFβ signalling 77 
(9,12). Fibroblasts do not express the IL6 receptor (10), so the soluble IL6 Receptor alpha (sIL6Rα) 78 
must be supplied in trans. A recent study (10), found that trans-IL6 signalling (IL6xRα) through 79 
STAT3 increased transcription of the matrix components Type I collagen and Fibronectin in80
hypertrophic scar fibroblasts, but not in normal skin fibroblasts. In addition to regulating the ECM and81
growth factor signalling, STAT 3 can contribute to fibrosis through its links to survival and82
proliferation (13). A key feature of fibroproliferative disorders is the abnormal persistence of83
myofibroblasts and their excessive proliferation leading to inappropriate connective tissue expansion84
(14). STAT3 may thus be contributing to myofibroblast persistence through resistance to apoptosis, so85
that the self-limiting wound healing response becomes self-perpetuating instead. (8, 15, 16). This86
process of apoptotic resistance and indeed the activation of profibrotic pathways, may be in part87
dependent on the balance between profibrotic STAT3 and anti-fibrotic STAT1 (15, 17). Finally,88
O’Donoghue et al (18) report that deletion of STAT3 protects mice from bleomycin induced fibrosis.89
In this study, we investigate specifically the role of STAT3 in the regulation of COL1 and other90
extracellular matrix proteins as well as TGFβ signalling in lung fibroblasts explanted from91
scleroderma patients and healthy volunteers. We report that STAT3 binds the COL1A2 enhancer in92
the HS4 region and directs activation cooperatively with JunB. We also report that STAT3 signalling93
is required for the production and remodelling of the extracellular matrix by fibroblasts.94
95
RESULTS96
STAT3 activates the COL1A2 far-upstream enhancer. The structure of the COL1A2 far97
upstream enhancer and the HS4 region is shown in figure 1a. An in-silico search for STAT3 binding98
sites identified two sites, 304 bp and 603 bp downstream of the critical AP-1 site, where JunB binds.99
Both sites are highly conserved. Additional sites were found near the proximal COL1A2 promoter100
(not shown).101
102
To investigate the interaction between STAT3 and the COL1A2 enhancer, we took advantage of103
the fact that fibroblasts explanted from scleroderma patients, typically contain a high proportion of104
myofibroblasts, with the COL1A2 enhancer active, even when they are deprived of serum or growth105
factor stimulation (3, 4). We created two different luciferase reporter gene constructs under the control106
of the COL1A2 enhancer and proximal promoter (3-5): A construct with the wild type enhancer (WT)107
and a mutant version (ΔHS4), missing the HS4 region containing the STAT3 and JunB sites (figure 108 
1b). Normal and SSc lung fibroblasts were transfected, with the constructs and treated with 100 µM109
AG490, an inhibitor of JAK2 and JAK3 (also EGFR, HER2), which reduces STAT signalling.110
Enhancer activation was determined by measuring luciferase expression (figure 1b). Scleroderma111
cells, as expected, showed markedly higher luciferase signalling compared with the normal cells but112
only with the wild-type construct. This increase was eliminated by AG490. In contrast both cell lines113
produced the same luminescence with ΔHS4 and AG490 had no effect. The results confirmed that 114 
STAT signalling is required and the HS4 region must be present to activate the COL1A2 enhancer,115
suggesting the STAT3 sites we found in the enhancer are functional.116
117
We assayed the physical binding of STAT3 to the HS4 region by chromatin immunoprecipitation118
(ChIP), using the more potent and selective JAK family inhibitor SD1029 (19). Scleroderma lung119
fibroblasts were serum starved and treated with 10 µM SD1029 or vehicle for 30 minutes prior to120
stimulation with IL6xRα (as described in methods) for a further 30 minutes. Following IL6xRα 121 
treatment, chromatin was immuno-precipitated with a monoclonal antibody against phosphorylated122
STAT3 (pSTAT3). End-point, PCR analysis of the precipitated chromatin DNA clearly detected the123
presence of the HS4 sequence, irrespective of IL6xRα treatment (figure 1c), showing that pSTAT3 is 124 
indeed bound to the HS4 region. Treatment with SD1029 strongly reduced binding (figure 1c).125
Surprisingly IL6xRα treatment made little difference to the binding of STAT3 to the enhancer 126 
suggesting that in myofibroblasts there is already sufficient STAT3 activation to ensure high127
occupancy of the STAT3 binding sites in the enhancer. The semi-quantitative approach was carefully128
set up to ensure saturation does not obscure the difference between the untreated and IL6 treated129
cells. We normalized the amount of DNA used in the assay based on an input sample collected before130
immunoprecipitation and limited the number of PCR cycles to prevent the reaction from getting too131
close to the plateau phase. Western blotting analysis of nuclear extracts from the treated cells132
confirmed that untreated cells contain nuclear pSTAT3, which was strongly increased by IL6xRα 133 
(figure 1d). SD1029 blocked the increase in STAT3 phosphorylation by IL6xRα (figure 1d). SD1029 134 
without IL6xRα, eliminated STAT3 phosphorylation (figure 1d). These findings are in agreement with 135 
the ChIP results.136
137
We investigated the functional consequences of STAT3 binding on promoter engagement by138
assaying JunB binding and RNA polymerase recruitment. When the enhancer is engaged it contacts139
the RNA polymerase complex forming at the collagen promoter. Thus, an RNA polymerase ChIP140
signal is a direct measure of enhancer engagement. Chromatin harvested from scleroderma lung141
fibroblasts treated overnight with SD1029 or vehicle was immunoprecipitated with antibodies against142
non-phosphorylated STAT3, JunB, and RNA polymerase II (RNApol II) (figure 1e). The amount of143
HS4 region DNA in the chromatin precipitated by each antibody was quantified by real time PCR.144
The results confirmed binding of all three proteins (figure 1e). Treatment with SD1029, reduced145
STAT3 and RNApol II binding, but had no effect on JunB binding. The results show that loss of146
STAT3 leads to enhancer deactivation and disengagement, even though JunB remains bound.147
Essentially the same results were obtained when STAT3 was knocked down with siRNA.148
149
STAT3 is required for collagen type 1 expression. We sought to confirm the ChIP results by150
investigating how modulation of STAT3 affects the transcription of COL1A2 in explanted lung151
fibroblasts. Cells from healthy controls or scleroderma patients were treated with IL6xRα and 7.5 µM 152 
SD1029 (figure 2a). As expected scleroderma cells expressed more COL1A2 and this increase was153
eliminated by SD1029 treatment, while expression in healthy control cells was unaffected (figure 2a).154
On the other hand, IL6xRα had no effect on COL1A2 mRNA expression at 24h (figure 2a). At the 155 
protein level SD1029 treatment reduced COL1 and fibronectin expression in scleroderma cells in a156
dose dependent manner (figure 2b). Critically, SD1029 treatment reduced both pSTAT3 and STAT3157
(fibure 2b). Since SD1029 inhibits all JAKs and may affect other signalling proteins, we verified that158
STAT3 is the key target using siRNA knockdown. Indeed, knockdown of STAT3 reduced COL1 and159
fibronectin mRNA expression in scleroderma lung fibroblasts (figure 2c). This is consistent with the160
results of the previous section, showing that STAT3 is vital for enhancer activation but in activated161
fibroblasts there is already sufficient STAT3 for the enhancer to function and additional activation of162
STAT3 by cytokines does not appreciably affect occupancy of the STAT3 sites in the enhancer.163
164
One alternative explanation for the lack of a COL1A2 transcriptional response with IL6xRα, is 165 
that activation of the enhancer is limited other components of the transcriptional complex that166
mediates enhancer activation (e.g. increased JunB/cJun balance), not affected by IL6xRα. If that is the 167 
case then we can expect a synergistic effect between TGFβ signalling and IL6 on COL1 expression.168
We treated serum starved SSc lung fibroblasts with both TGFβ and IL6xRα for 24h and quantified 169 
COL1A2 mRNA levels (figure 2d). We found that IL6 trans-signalling did not synergise with TGFβ 170 
in upregulating COL1A2 transcription. On the other hand, SD1029 treatment effectively suppressed171
the upregulation of COL1A2 by TGFβ (figure 2d).  172 
The lack of synergy could also be explained by the differences in signalling between TGFβ and 173 
IL6xRα however. The STAT3 upregulation produced by IL6xRα is short lived and therefore it is 174 
possible that the increased STAT3 activation does not last long enough to synergize with TGFβ. 175 
176
Is sustained IL6/sIL6R signalling required for collagen 1 expression? To examine this177
possibility, we conducted a series of time-course experiments measuring the intracellular protein178
expression of STAT3, pSTAT3, COL1A1, and COL1A2, as well as the TGFβ responsive,179
myofibroblast related genes SERPINE1, EDA-FN1, and FN1. We treated serum-starved scleroderma180
fibroblasts with IL6/sIL6R for 0.5, 2 or 16 hours. We used two controls one at 0.5h and at 2h, to181
account for the changing basal expression levels. All comparisons were done with the appropriate182
control. (figure 3a).183
184
At the protein level, IL6xRα treated cells at 0.5h, showed a 2-fold upregulation of 185 
fibronectin/EDA-fibronectin and a 1.5-fold upregulation of collagen type I (n=3, both significant, p186
<0.05 with the Student’s T-test) relative to the untreated control at 0.5h (figure 3a). This upregulation187
was lost after 2h (figure 3a). Collagen is a secreted protein, and therefore we also investigated the188
effect of IL6 and SD1029 on the secreted COL1 protein levels of scleroderma or normal lung189
fibroblasts cultured for 16h (figure 3b). IL6 resulted in a clear increase in secreted collagen and this190
increase was suppressed by 7.5 µM SD1029. Real time PCR analysis of COL1A1, COL1A2 and191
EDA-fibronectin mRNA levels, showed an upward trend which was not statistically significant (figure192
3c). Once again there is no transcriptional upregulation of COL1A2 in response to IL6, but we193
observed a rapid effect on protein levels, tracking the pSTAT3 levels. In particular, at the 30-minute194
time point, there is not enough time for any transcriptional effect to meaningfully alter protein levels195
and hence this must reflect a post-transcriptional effect. It is important to note that collagen protein196
levels reflect a balance between translation, processing and secretion, so STAT3 could be affecting197
any of these processes to produce rapid changes in intracellular COL1 protein levels. Using the198
mRNA extracted from these cells, we then investigated the activation of the STAT3 negative feedback199
loop by measuring SOCS3 mRNA expression (figure 3d). We found weak upregulation of SOCS3 at200
30 minutes, but a dramatic upregulation at 2 hours. The STAT3 negative feedback loop (7) is201
responsible for the rapid shutdown of STAT3 signalling following a single dose of IL6/sIL6R. At 16h,202
SOCS3 expression had reverted to background levels.203
204
We reasoned that using two doses of IL6, would result in a more prolonged activation of STAT3205
(schematic on figure 4a) and therefore if there is any synergy between TGFβ and IL6 it would give us 206 
a better chance to observe it. We treated the cells with two doses of IL6xRα, separated by 4h. TGFβ207
was only co-administered with the first dose of IL6/sIL6R (figure 4a). Western blot analysis at 16h208
(figure 4b, lanes 1&2) showed a robust phospho-STAT3 signal, confirming that two doses of209
IL6/sIL6R produce sustained STAT3 activation. Expression of COL1 protein was somewhat higher210
with IL6/sIL6R whereas the levels of EDA-FN1, αSMA and SERPINE1 remained unchanged at 16h 211 
(figure 4b, lanes 1&2). Again, there was no increase in the transcription of these genes with IL6xRα 212 
alone (figure 4c).213
214
TGFβ treatment modestly increased STAT3 phosphorylation (figure 4b, lane 3). A combination215
of TGFβ and two doses IL6xRα showed the same STAT3 activation as two-doses of IL6xRα alone 216 
(figure 4b, lanes 2 & 4). The robust activation of COL1, EDA-FN1, SERPINE1 (mRNA and protein)217
or αSMA (protein) by TGFβ, was the same irrespective of IL6xRα addition (figure 4b, lanes 3 & 4 218 
and figure 4c). Therefore, our data is only consistent with our original hypothesis. Even though TGFβ 219 
requires STAT3 there is no obvious synergy on the COL1A2 transcriptional level between IL6 and220
TGFβ, under these experimental conditions because TGFβ activates STAT3 on its own sufficiently to 221 
support full activation of the enhancer.222
223
Finally, we examined whether STAT3 is needed for early or late TGFβ signalling. We treated 224 
cells with SD1029, TGFβ and IL6 for 4h and then a second dose of IL6 was added to relieve the 225 
inhibition on STAT3 (schematic on figure 4a). The second IL6xRα dose restored phosphoSTAT3 226 
levels (figure 4b, lane 5 & 7) while in cells treated with TGF alone, SD1029 completely blocked any227
activation of STAT3 (figure 4b, lane 6). We found the restoration of STAT3 levels after 4 hours,228
failed to relieve the inhibition of TGFβ signalling. The effect of TGFβ on the expression of COL1, 229 
EDA-FN1, SERPINE1 (mRNA and protein) or αSMA (protein) was still abrogated (figure 4b, lane 5-230 
7, and figures 4c, 4d).231
232
Basal levels of STAT3 in scleroderma. If our hypothesis is correct, then the variation in STAT3233
levels between normal and scleroderma fibroblasts should be too small to observe and we can expect234
constitutive basal STAT3 activation in fibroblasts from both healthy controls (which have few235
myofibroblasts) and scleroderma patients (which have a lot of myofibroblasts). We measured STAT3236
activation after serum starvation in lung fibroblasts explanted from 3 different healthy controls and 3237
different scleroderma patients (figure 5a & b). As expected, we found similar levels of STAT3238
phosphorylation (figure 5b). There was very small upward trend towards scleroderma, but it was not239
statistically significant. Individual variation between cell lines was considerable with high STAT3240
expression and phosphorylation correlating to higher COL1 and FN1 expression. We confirmed this241
result by looking at pSTAT3 levels in lung sections obtained from patients and healthy controls using242
immunohistochemistry (figure 5c). STAT3 phosphorylation was observed, but the proportion of243
phosphoSTAT3 positive nuclei did not differ between control healthy and scleroderma fibrotic lung244
tissue (40.3% control vs 37.4% for SSc).245
246
JAK/STAT signalling, the extracellular matrix and myofibroblast function. Given the strong247
impact of SD1029 on matrix protein synthesis and TGFβ signalling, we investigated the inhibition of248
key cytoskeletal and ECM rearrangements involved in myofibroblast transition. Using three colour-249
immunofluorescence, we assessed expression of type I pro-collagen and EDA-fibronectin levels as250
measures of extra-cellular matrix biosynthesis (figure 6a). We used a specific antibody for Type I pro-251
collagen, which is unprocessed and only found intracellularly, making it is a better indicator of the252
collagen synthesis rate. We also used a specific antibody against EDA fibronectin which is an253
essential component of the ECM laid down specifically by myofibroblasts. Scleroderma lung254
fibroblasts showed strongly increased pro-collagen levels and laid down a much more extensive EDA-255
fibronectin network compared to normal cells (figure 6a). Treatment with SD1029, had little effect on256
normal cells, but it normalised the scleroderma cell phenotype (figure 6a).257
258
To assess cytoskeletal rearrangement and stress fibre formation, we stained the fibroblasts with259
Phalloidin and a specific antibody against αSMA (figure 6b). TGFβ treatment increased the number of260
αSMA-containing stress fibres. The response of scleroderma fibroblasts was much more pronounced 261 
compared to normal fibroblasts (figure 6b). SD1029 treatment effectively blocked the increased262
formation of αSMA containing stress fibres (figure 6b), showing that cytoskeletal re-arrangements in 263 
response to TGFβ were blocked.  264 
265
We used collagen contraction assays to measure the effect of STAT3 inhibition with SD1029 or266
knockdown with siRNA on contractility, a key feature of the myofibroblast phenotype. Both STAT3267
siRNA and SD1029 effectively prevented the fibroblasts from contracting the collagen gels in268
response to TGFβ (figure 6c). In contrast, the effect of SD1029 in the scratch wound assay which269
measures fibroblast migration was not statistically significant (figure 7).270
271
Effects of JAK/STAT3 signalling, on translation. Given that our results hinted at a possible272
post-transcriptional effect on collagen and fibronectin protein production in response to IL6 treatment,273
we conducted a brief investigation of two initiation factors known to be regulated by STAT3: eIF2α274
and eIF4e. Recently, a role for STAT3 in autophagy and the control of translation was reported (20),275
with STAT3 enhancing eIF2 activity by preventing alpha subunit hyper-phosphorylation. In addition,276
it has been reported that IL6 signalling via STAT3 feeds into mTOR/S6/eIF4e pathway (21).277
Activation of eIF4e, is accomplished through deactivation of its inhibitor 4EBP1 through278
phosphorylation.279
280
The results are shown in figure 8. Surprisingly there is little eIF2a phosphorylation to begin with281
and IL6 results in a minor increase rather than a decrease. Conversely phosphorylation of 4EBP1 was282
strongly activated by IL6 treatment. Another interesting result was that eIF2α phosphorylation 283 
declines later on at 16h. This offers an interesting explanation for our observation that leaving the cells284
to recover from serum starvation overnight also results in collagen and fibronectin protein production285




The molecular control of collagen expression and fibroblast to myofibroblast transition is of290
considerable medical interest, because of their central role in fibrosis. Fibrosis and lung fibrosis291
specifically is a major cause of death (1,2) in patients with fibrotic diseases such as SSc (1,2).292
Understanding, the nature of the dysregulation in the production of COLI offers vital clues on the293
dysregulation of extracellular matrix deposition and remodelling in fibrosis. In this report, we show294
that STAT3, together with JunB, is a key part of the machinery that activates the COL1A2 enhancer295
and therefore regulates COL1 production. Inhibition of JAK/STAT signalling or STAT3 knockdown296
prevented enhancer activation and RNA polymerase recruitment without affecting JunB binding.297
Based on these results, our proposed model for the activation of the COL1A2 enhancer by JunB and298
STAT3 is shown in figures 9a and 9b.299
300
One important finding is that although IL6-trans signalling strongly increased STAT3 activation,301
it did not appreciably change the amount of STAT3 bound to the COL1A2 enhancer or the mRNA302
level of COL1A2. Indeed, all our results are consistent with the hypothesis that enhancer activation in303
human lung fibroblasts is not limited by the availability of STAT3, because there is already significant304
basal STAT3 activation in fibroblasts. STAT3 expression and phosphorylation, as well as binding of305
COL1A2 to the COL1A2 enhancer are readily detectable in untreated fibroblasts. Similarly, inhibition306
of STAT3 phosphorylation results in loss of both pSTAT3 and total STAT3 (figure 2b), in agreement307
with the well-known that STAT3 itself is a well-known target of phosphorylated STAT3 (22).308
However, the impact of STAT3 phosphorylation on STAT3 expression is limited by the induction of309
SOCS3, which is also a pSTAT3 target. Addition of IL6 does not appreciably increase STAT3310
expression despite IL6 treatment, showing that there is already sufficient STAT3 activity to maintain311
high STAT3 expression and that further increases in phosphorylated STAT3 have no effect due to the312
induction of SOCS3 (figure 3d). An important question left unanswered by our study is whether non-313
phosphorylated STAT3, which is a functional transcription factor (22), can also activate the collagen314
1A2 enhancer. This may be an additional reason for the lack of a clear transcriptional effect with IL6315
on COL1A2. In any case, our results clearly show that STAT3 is naturally activated by TGFβ, so 316 
independent activation of STAT3 may not be necessary to support full activation of the enhancer.317
This explains the apparent lack of synergy between TGFβ and IL6.318
319
Despite the lack of transcriptional activation, we see a consistent increase in COL1 and FN1320
protein levels with IL6 trans-signalling, strongly suggesting a post-transcriptional effect. We present321
results that suggest IL6 signalling feeds into the mTOR/S6/eIF4e pathway, offering a very plausible322
model for the effects of the protein we have observed. IL6 signalling clearly increases 4EBP1323
phosphorylation, which relieves its inhibition of eIF4E. This is in agreement with previous results324
published by our group on skin fibroblasts, where a clear increase in protein expression was observed325
(23)326
327
Our work therefore, suggests a dual role for STAT3 in TGFβ signalling: Aside from its functions 328 
as a transcription factor, it also activates the translational machinery. We believe that this explains the329
clear relationship that we observed between TGFβ and STAT3 signalling and the reason why 330 
JAK/STAT inhibition appears so effective at shutting down TGFβ signalling.  331 
332
TGFβ has long lasting effects on fibroblasts, which are dependent on early signalling initiating a 333 
self-reinforcing process of ECM modification and integrin signalling activation (24) that culminates in334
the creation of a high mechanical tension environment and the establishment of a TGFβ autocrine loop335
(25). This is well illustrated by our data. In figure 3 it can be seen that after fibroblasts are switched336
into serum free media, the expression of matrix proteins and at the same time STAT3 phosphorylation337
increases over time without any treatment, reflecting conditioning of the media by TGFβ and other338
cytokines/growth factors. Once this process is completed the myofibroblast phenotype becomes339
relatively stable. Our results suggest that STAT3 has a direct role in this process. Rather than activate340
separate pathways that feed into and enhance TGFβ function, STAT3 is actually part of the TGFβ 341 
signalling pathway: STAT3 is partially activated by TGFβ and it is directly involved in downstream342
transcriptional responses. High level activation of STAT3 by cytokines may enhance sensitivity or343
speed up the process but the eventual outcome is the same. This is exemplified by the western blotting344
results in figure 3a.345
346
However, inhibition of STAT3 blocks production of matrix protein components both at the347
transcriptional and post-transcriptional level, preventing TGFβ from initiating the matrix remodelling 348 
process, which is an integral part of the myofibroblast transition. This explanation is completely349
consistent with our observations: STAT3 inhibition potently blocked matrix protein (COL1/FN1)350
synthesis, the deposition of an EDA-fibronectin network, the appearance of αSMA containing stress 351 
fibres and consequently fibroblast contractility. The importance of STAT3 in these early events is352
demonstrated by the fact that overriding STAT3 inhibition 4 hours after addition of TGFβ fails to353
rescue the powerful inhibitory effect of SD1029 on TGFβ signalling as seen in figure 4. Based on354
these results, we present a model for the interaction between STAT3 and TGFβ in lung fibroblasts in 355 
figure 9c.356
357
Our results offer a new understanding of the avenues of interaction between pro-fibrotic and358
inflammatory signalling, which underlies the transition of human lung fibroblasts to myofibroblast.359
Cytokine signalling appears to potentiate pro-fibrotic signalling rather than synergize with it. They360
create a permissive effect lowering the threshold at which TGFβ and presumably other pro-fibrotic 361 
mediators can initiate the myofibroblast differentiation process. This offers a compelling explanation362
for our results and helps explain the variability in response between different fibroblast lines.363
364
The differences between fibroblasts of different lineages are particularly relevant. Lung365
fibroblasts show distinct properties compared with dermal fibroblasts: For example, O’Reilly et al366
(12) and Ray et al (10), both report increases in collagen and fibronectin mRNA levels with IL6367
treatment in dermal fibroblasts, but the underlying process appears to be completely different.368
O’Reilly et al show a delayed response, which they attribute to IL6 upregulating gremlin, while Ray et369
al see an instant transcriptional response with IL6. In contrast Pechkovsky et al (8) found no370
transcriptional effects in lung fibroblasts, in agreement with our results. These differences can be371
reconciled through variations in basal activation levels of STAT3 and the TGFβ autocrine loop, 372 
between different fibroblast lines.373
374
Pedroza et al (9) appear at first glance to arrive at a different conclusion. However, upon close375
inspection of their data, it can be seen that our results are compatible. In their experiments, Pedroza et376
al, normalize pSTAT3 levels to a house keeping gene, but a closer look at their results shows that377
there is no obvious change in the level of STAT3 phosphorylation. Although a clear case can be made378
that an absolute increase in STAT3 means more pSTAT3, if this is driven by increased JAK/STAT379
signalling, it must necessarily be accompanied by an increase in STAT3 phosphorylation. Yet Pedroza380
et al, find only increased STAT3 expression and no obvious change in STAT3 phosphorylation.381
Importantly, there is considerable variation in STAT3 expression even in the normal cells. It is382
certainly possible that genetic factors leading to increased STAT3 expression may have an important383
role to play in idiopathic pulmonary fibrosis, but the Pedroza et al data, do not contradict our findings.384
More interesting is the finding that IL6 signalling activates collagen expression in mouse lung385
fibroblasts from the bleomycin model. No comparable results are presented with the IPF fibroblasts386
that Pedroza et al, clearly have at their disposal. We suspect this may be a critical difference between387
mouse and human lung fibroblasts.388
389
Overall, we believe our data are instrumental to resolving long-standing questions on the role of390
cytokine signalling in the fibroblast to myofibroblast transition, posed by the disparities in the391
literature. JAK/STAT signalling is integrated with pro-fibrotic signals, rather than feeding into them392
and STAT3 has both transcriptional and post-transcriptional roles to play. As a transcription factor, it393
controls COL1A2 expression through binding to its enhancer as a part of a complex that contains AP-394
1 (e.g. JunB) and presumably other factors. Such transcriptional complexes tend to regulate multiple395
related genes simultaneously, so we expect that other matrix related genes are controlled in a similar396
fashion. At the same time, through its role in translation and autophagy STAT3 appears to help397
regulate directly the production of various TGFβ inducible proteins. This combined dual role of 398 
STAT3 and the fact that TGFβ itself induces STAT3 phosphorylation, can lead to divergent 399 
experimental outcomes depending on the experimental model used and idiopathic factors such as the400
underlying level of STAT3 expression.401
402
Finally, our report firmly establishes STAT3 as critical component of the fibroblast extracellular403
matrix remodelling mechanism in the lung and therefore as a target for anti-fibrotic therapy. Although404
targeting cytokines may be beneficial in ameliorating some aspects of SSc, as evidenced by promising405
clinical data for toclizumab, an IL6 receptor blocking antibody, in skin fibrosis (26), we believe that406
STAT3 also represents a compelling target.407
408
MATERIALS AND METHODS409
Patients and cell culture. Fibroblasts were explanted from post-mortem scleroderma or healthy410
control lung biopsy samples. Each fibroblast line used in this study was derived from a distinct411
individual. They were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal412
bovine calf serum and used only between passages 2 and 5.413
Reagents. Antibodies to STAT3 and phosphoSTAT3 were obtained from Cell Signalling414
technologies. Antibodies to JunB and RNA polymerase II as well as rabbit IgG were obtained from415
Santacruz. The TBP antibody was obtained from Abcam. The Fibronectin antibody was obtained from416
BD Transduction Laboratories. SD1029 and AG490 were obtained from calbiochem. All DNA417
primers were obtained from Integrated DNA technologies. TGFβ, IL6 and IL6Rα were obtained from 418 
R&D systems.419
Transcription factor binding site in-silico analysis. Analysis of STAT3 binding to the420
COL1A2 enhancer was carried out using the Transfac Match program (27) and the Jaspar database421
(28) using STAT-specific matrices. The degree of conservation for each site was checked using the422
Galaxy UCSC genome browser (29,30).423
DNA constructs and transient transfections. The human collagen FUE region and the424
preparation of the HS1-5 (referred to in the text as WT) and ΔHS4 constructs has been described 425 
previously (3,5). Transient transfection assays were performed using FuGene 6 transfection reagent426
according to the manufacturer's instructions. Briefly, 2*105 cells (normal or scleroderma) per427
transfection were seeded in 6-well plates and transfected with 2 μg of total plasmid DNA. A renilla 428 
luciferase plasmid under the control of the Rous Sarcoma Virus (RSV) promoter was used to control429
for transfection efficiency. The following day the cells were serum starved overnight with 0.1% BSA430
in DMEM, prior to treatment with 150 µM AG490 or vehicle control (DMSO) for 24 hours. The cells431
were finally harvested using a Dual-Light Chemiluminescent reporter gene assay system (Tropix)432
according to the manufacturer's instructions. The experiment was run in triplicate and repeated three433
times.434
IL6 treatment. IL6 (10 µg/mL) was premixed with an equal volume of the soluble IL6 receptor435
alpha (25 µg/mL) in PBS, to obtain an equimolar mixture (IL6xRα). IL6xRα was used at 15 ng/mL 436 
final IL6 concentration (1.5/1000 dilution)437
Chromatin Immunoprecipitation. ChIP assays were performed using the EZ ChIP assay kit438
from Merck-Millipore, according to the manufacturer’s instructions. Briefly the cells were seeded in439
10 cm plates at 2*106 cells per plate and treated as described in the results sections. The chromatin440
was crosslinked with 1% formaldehyde in media, for 10 minutes at 37oC. The cells were lysed with441
SDS-lysis buffer and the chromatin DNA was sheared to 400bp average by sonication. Protein A442
sepharose beads and specific antibodies (phosphoSTAT3, JunB, RNA polymerase II) were used for443
immunoprecipitation with Rabbit IgG as the negative control. The precipitated DNA was analysed444
qualitatively by endpoint PCR, using the QIAGEN Fast Cycling PCR kit or quantitatively by real time445
PCR (see below) using primers specific for the HS4 region: Fwd –446
TTCACATGAGCATTTGAGTGTATTG and Rev – TCGTCAGTGTGTAACCCTCATC.447
RNA interference. SiRNA against STAT3 was obtained from GE Dharmacon (USA) and448
transfected using dharmafect 1 according to the manufacturer’s instructions. Fibroblasts were seeded449
in 25cm2 flasks at 75% confluence and transfected with 25 nM siRNA. The next day the fibroblasts450
were serum starved with 0.1% BSA in DMEM for 24h and then used for further experiments.451
Western Blotting. The Thermo-Fisher NuPAGE system was used for western blotting according452
to the manufacturer’s instructions. Whole cell lysates were prepared in RIPA buffer and 10-15µg of453
protein were loaded per 15-well lane. Nuclear extracts were prepared with the Thermo-Fisher NE-454
PER kit according to the manufacturer’s instructions. 2.5-5µg of protein were loaded per 15-well lane.455
Quantitative PCR. Real time PCR analysis was accomplished using a QIAGEN Rotorgene 6000456
thermal cycler with the QIAGEN QuantiFAST RT-PCR kit according to the manufacturer’s457
instructions. For quantification of ChIP DNA, the reverse transcriptase step was omitted and the458
results were normalised based on a sample of the chromatin (input) obtained just before the459
immunoprecipitation step. For the analysis of Gene expression total RNA was isolated using the460
QIAGEN RNeasy kit according to the manufacturer’s instructions and Tata Binding Protein (TBP)461
was used as the house keeping gene. Primer sequences are in table 1.462
463
Table 1: Primers used for quantitative real time PCR464







Immunohistochemistry. Lung biopsy specimens obtained from SSc patients or healthy controls466
were fixed in formalin and paraffin embedded. Immunohistochemistry was accomplished as described467
previously (4), using an antibody specific for phosphorylated STAT3. The number of cells positive468
and negative for nuclear phosphoSTAT3 were counted using Image J.469
Immunofluorescence. The cells were seeded in 8-chamber slide at a density of 2*104 cells per470
chamber and allowed to attach overnight. The next day the fibroblasts were serum starved with 0.1%471
BSA in DMEM for 24 h, prior to treatment with TGFβ (2 ng/mL) and SD1029 (10 µM). 472 
Immunofluorescence was carried out as described previously (4), using antibodies against EDA-473
fibronectin (mouse - Abcam), pro-collagen1 (rat - Abcam) and αSMA (mouse - DAKO). Phalloidin 474 
texas red (Life technologies) where indicated was added along with the secondary antibody at a475
1:1000 dilution.476
Gel contraction assays. A collagen mixture containing 1 part 0.2M HEPES pH 8 .0 (Sigma), 4477
parts 2.05 mg/mL rat tail collagen type I (First Link UK Ltd) and 5 parts DMEM was prepared on ice.478
Fibroblasts were added at 8*104 cells/mL and the cell-collagen mixture was added to 24 well plates479
(1mL per well). SD1029 were appropriate was added to the collagen mixture (1-10 µM). The plates480
were incubated at 37oC for 1h to allow the collagen to gel and overlayed with 1 mL DMEM. TGFβ, 481 
where appropriate, was added to the media at 2ng/mL. The plates were incubated at 37oC overnight482
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FIGURE LEGENDS589
Figure 1: (A) The structure of the COL1A2 far upstream enhancer (FUE) showing the proximal590
promoter (PP) three of the five DNAse hypersensitive sites (HS3-5), the critical AP-1 element in HS4591
and the two putative STAT3 sites (arrows indicate DNA strand). (B), Reporter gene analysis of592
enhancer activation in normal (n=3) and SSc (n=3) lung fibroblasts treated with the JAK/STAT593
inhibitor AG490. The structure of the two DNA constructs used is shown on the top. The WT594
construct contains all elements of the FUE and PP fused to the firefly luciferase gene, while in ΔHS4 595 
the HS4 region has been deleted to inactivate the enhancer. The results are normalized using a renilla596
luciferase transfection control (C) DNA gel showing the results of a ChIP assay for phosphoSTAT3597
near the HS4 region in SSc lung fibroblasts treated with IL6 plus the soluble receptor alpha (IL6xRα) 598 
and SD1029. (D) Western blot of nuclear extracts from the same cells used in (C), showing nuclear599
phosphoSTAT3 levels. Tata Binding Protein (TBP) was used as the house keeping gene. (E) ChIP600
analysis using qPCR for the binding of STAT3, JunB and RNA polymerase II, in the HS4 region of601
SSc fibroblasts after treatment with SD1029, or STAT3 siRNA (siSTAT3) or non-targeting siRNA602
(siNT). * = p < 0.05603
604
Figure 2: (A) Normal and scleroderma fibroblasts (n=3, * = P <0.05 by Student’s t-test) treated with605
IL6xRα and SD1029. (B) The effect of SD1029 on STAT3 Y705 phosphorylation, FN1 protein and 606 
COL1 protein in serum starved scleroderma lung fibroblasts. (C) The effect of STAT3 downregulation607
with siRNA on COL1A2 and EDA-fibronectin mRNA expression in scleroderma lung fibroblasts608
(n=3, * = P <0.05). (D) Serum starved scleroderma lung fibroblasts were treated with IL6xRα, TGFβ 609 
and SD1029 for 24h the cells, prior to assaying COL1A2 mRNA levels (n=3, * = P <0.05).610
611
Figure 3: (A) Serum starved lung scleroderma fibroblasts (n=2) were treated with IL6xRα for 0.5. 2 612 
or 16h or left untreated. Protein was analysed by western blotting and densitometry. A representative613
blot matching the average is shown. The first histograph shows the normalized density of the bands in614
the western shown here. The other histogram on the right, shows the average normalized collagen615
levels from three independent experiments each with a different fibroblast line (n=3). * = p <0.05. (B)616
Transcriptional analysis of COL1A1, COL1A2 and EDA-FN1 from the cell lines (n=2) treated as in617
(A). (C) Analysis of COL1 in the media of scleroderma (SSc) and healthy control lung fibroblasts618
treated with IL6xRα with or without 7.5 µM SD1029 for 16h. (D) Transcriptional analysis of SOCS3 619 
in response to IL6xRα. * = p < 0.05 620 
621
Figure 4: (A) Schematic illustrating the treatment regime. Serum starved SSc fibroblasts were treated622
with 2 doses of IL6xRα 4 hours apart. TGFβ, where appropriate was added together with the first 623 
IL6xRα. SD1029 was only added just before the first IL6xRα treatment at zero hours.  (B) Protein624
level analysis of treated cells by western blotting and densitometry. (C, D) Transcriptional analysis of625
COL1A1, COL1a2, EDA-FN1 (D) and SERPINE1 (PAI-1) (E).626
627
Figure 5: (A) Three normal and three scleroderma lung fibroblasts were serum starved overnight and628
western blotting used use to determine STAT3 phosphorylation. The ratio of pSTAT3 to STAT3 was629
determined by densitometry (arbitrary units). (B) Levels of STAT3 phosphorylation from (A)630
averaged for scleroderma and normal fibroblasts. Statistical analysis was done with the Student’s T-631
test. (C) Immunohistochemistry for STAT3 in lung sections from normal volunteers and scleroderma632
patients.633
634
Figure 6: (A) Immunofluorescence for Type I pro-collagen (green) and EDA-fibronectin (red) in635
normal and scleroderma serum starved lung fibroblasts treated with SD1029. (B) Immunofluorescence636
for alpha SMA (green) in normal and scleroderma lung fibroblasts treated with TGFβ and SD1029. 637 
The actin cytoskeleton was stained red with phalloidin. (C), Collagen gel contraction assay (n=3, * =638
P<0.05 with a student’s t-test) in scleroderma cells treated with TGFβ, SD1029, siRNA against 639 
STAT3 or non-targeting (NT) siRNA. Normal fibroblasts failed to contract the gel sufficiently to640
achieve statistical significance.641
642
Figure 7: Scratch wound assay with a scleroderma lung fibroblast line and SD1029. The cells were643
plated in 24 well plates, allowed to reach confluence and serum starved overnight with 0.1% BSA in644
DMEM. A scratch was made with a pipette tip and mitomycin C was added to prevent proliferation.645
The cells were allowed to migrate overnight with or without 10 µM SD1029. The experiment was646
carried out in triplicate. The area of the gap was measured with ImageJ and % closure was calcuated647
as (area at 24hours)/(area at 0 hours)*100. The differences between untreated and SD1029 treated648
were not statistically significant with a Student’s T test.649
650
Figure 8: The effect of IL6 on the eIF2α and eIF4e pathways. Primary lung fibroblast cultures from 651 
SSc patients, were serum starved overnight. The media was replaced with fresh serum free media652
containing IL6xRα or the equivalent volume of PBS and protein was harvested after 30 min, 2h or 653 
16h. STAT3 phosphorylation is shown as a positive control for IL6. eIF2α phosphorylation was 654 
investigated as a measure of eIF2α de-activation and 4EBP1 expression/phosphorylation was 655 
investigated as a measure for eIF4e activation.656
657
Figure 9: (A) Interaction between the COL1A2 enhancer and promoter in the presence of STAT3. (B)658
The enhancer without STAT3. STAT3 acts as a bridge helping to engage the promoter and enhancer,659
while JunB recruits RNA polymerase. (C) The role of STAT3 in early TGFβ signalling. Basal STAT3 660 
signalling and STAT3 directly induced by TGFβ is sufficient to interact with AP1/JunB and together 661 
with SMADs induce early transcriptional activation of matrix proteins. High STAT3 activation662
enhances translation. The increased expression of pro-fibrotic matrix proteins, triggers matrix663
remodelling, reinforces the TGFβ autocrine loop and initiates myofibroblast differentiation.  664 
665









